Compare Twist Bioscience Corp (TWST) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Twist Bioscience Corp trades at $124 (market cap $7.72B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.38. The key difference: Twist Bioscience Corp is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| TWST | YMAG | |
|---|---|---|
Market Cap | $7.72B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $124.88 | $15.98 |
52-Week Low | $24.16 | $10.76 |
Enterprise Value | $7.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.58, up 0.87% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.07 to $0.40 per share. News highlights ongoing distribution announcements and analysis of its option income strategy, though key financial ratios are not provided in the data.
The outlook hinges on YMAG's ability to sustain high distributions through its option strategy, but earnings volatility in underlying holdings poses a risk to NAV stability. Investor sentiment is mixed, with some analysts viewing it as a tactical buy in rangebound markets, while others caution on compounded decay across its seven underlying ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
